Inositol as a lipotropic agent in dairy cattle diets.
Fatty liver syndrome or hepatic lipidosis (HL) is a condition thought to contribute to an increased incidence of peripartum disease, reduced response to therapy and decreased fertility in dairy cows. This syndrome is characterized by excess triglyceride (TG) accumulation in the liver and apparent decreased hepatic lipoprotein output. In lactating rats, a similar condition results from feeding an inositol-deficient diet. It is also characterized by excess hepatic TG accumulation and decreased hepatic lipoprotein output. Myo-inositol is a necessary component of the phospholipid phosphatidyl-inositol, which is an important membrane constituent. Myo-inositol occurs in feed mainly as the inositol hexaphosphate phytic acid. Phytic acid is undigestible by the monogastric but rumen phytases are assumed to adequately hydrolyze it. In early lactation dairy cows, lipid mobilization is intense, and the myo-inositol requirement may exceed the dietary supply or availability. Myo-inositol is being tested in a field trial as a potential lipotropic agent for dairy cows. Preliminary results suggest no lipotropic benefit from added myo-inositol.
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000378:metabolism / Q000517:prevention & control*; D005234:Fatty Liver / Q000378:metabolism / Q000517:prevention & control / Q000662:veterinary*; D005260:Female; D005527:Food, Fortified; D007294:Inositol / Q000008:administration & dosage* / Q000378:metabolism; D007328:Insulin / Q000097:blood; D008099:Liver / Q000378:metabolism; D011247:Pregnancy; D011644:Puerperal Disorders / Q000378:metabolism / Q000517:prevention & control / Q000662:veterinary*; D013577:Syndrome / Q000662:veterinary; D014280:Triglycerides / Q000378:metabolism
D007328:Insulin; D014280:Triglycerides; D007294:Inositol